Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25122727 | 0.85 | PPARG (0.40) | CYP4F2CYP4A11PPARGPPARA | |
| SCHEMBL23845279 | 0.84 | CYP4F2 (0.37) | CYP4F2CYP4A11PPARGPPARA | |
| SCHEMBL27064513 | 0.81 | CNR2 (0.41) | — | |
| SCHEMBL29307149 | 0.76 | CYP4F2 (0.36) | CYP4F2CYP4A11PPARGPPARAALOX5 | |
| SCHEMBL26224388 | 0.74 | CYP1A2 (0.41) | CYP4F2CYP4A11PPARGPPARAALOX5 | |
| SCHEMBL22526055 | 0.73 | CYP4F2 (0.41) | CYP4F2CYP4A11PPARGPPARA | |
| SCHEMBL25122669 | 0.72 | BCHE (0.41) | PPARGPPARAALOX5 | |
| SCHEMBL16981025 | 0.71 | CYP4F2 (0.43) | TTRALBCYP4F2CYP4A11 | |
| SCHEMBL23475823 | 0.71 | FAAH (0.46) | — | |
| SCHEMBL23842320 | 0.71 | PPARG (0.40) | PPARGPPARAALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | TTR 2894/4885ALB 2586/4885CYP4F2 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.